Literature DB >> 11697682

Dementia in Parkinson's disease.

A D Korczyn1.   

Abstract

Advanced Parkinson's disease (PD) is frequently associated with dementia. The pathogenesis of this dementia is complex, related to deficiency of several biogenic amines and cortical Lewy body deposition, as well as co-existent age-related brain changes, both of the Alzheimer's type and vascular. However, degeneration of the cholinergic neurons in the nucleus basalis of Meynert may have an important contribution to the cognitive decline. The dementia of PD has a grave effect on the quality of life of the patients and their caregivers, as well as negative effect on their survival. The treatment of dementia associated with PD therefore must encompass several agents. We have treated several patients with the cholinesterase inhibitor rivastigmine which produced gratifying results. Future studies should define the exact role of this agent in the treatment of the dementia of PD.

Entities:  

Mesh:

Year:  2001        PMID: 11697682     DOI: 10.1007/pl00022916

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  Neuropsychiatric phenomena associated with movement disorders.

Authors:  Joshua L Roffman; Todd Eisenberg; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

Review 3.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

4.  Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia.

Authors:  N I Bohnen; D I Kaufer; R Hendrickson; L S Ivanco; B J Lopresti; G M Constantine; Ch A Mathis; J G Davis; R Y Moore; S T Dekosky
Journal:  J Neurol       Date:  2005-09-02       Impact factor: 4.849

Review 5.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

Review 6.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 7.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 8.  The cholinergic system and Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

9.  Cognitive-enhancing effect of quercetin in a rat model of Parkinson's disease induced by 6-hydroxydopamine.

Authors:  Napatr Sriraksa; Jintanaporn Wattanathorn; Supaporn Muchimapura; Somsak Tiamkao; Kamoltip Brown; Kowit Chaisiwamongkol
Journal:  Evid Based Complement Alternat Med       Date:  2011-07-18       Impact factor: 2.629

10.  Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

Authors:  Giuseppe Battaglia; Carla L Busceti; Gemma Molinaro; Francesca Biagioni; Marianna Storto; Francesco Fornai; Ferdinando Nicoletti; Valeria Bruno
Journal:  J Neurosci       Date:  2004-01-28       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.